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Background: Cytotoxic drugs like doxorubicin remain as the most utilized agents in sarcoma 
treatment. However, advanced sarcomas are often resistant, thus stressing the need for new 
therapies aimed to overcome this resistance. Multi-kinase inhibitors provide an efficient way to 
target several pro-tumorigenic pathways using a single agent and may constitute a valuable 
strategy in the treatment of sarcomas, which frequently show an aberrant activation of pro-
tumoral kinases. Therefore, we studied the antitumor activity of EC-70124, an indolocarbazole 
analog that have demonstrated a robust ability to inhibit a wide range of pro-survival kinases. In 
addition, we analyzed the ability of EC-70124 to prevent drug resistance and synergize with 
doxorubicin. 
Methods: We used both cell-of-origin models of sarcoma and sarcoma patient-derived primary 
cell lines. Cell survival, apoptotic induction, cell cycle progression, DNA damage and the 
existence of a synergistic interaction were analyzed after drug treatments. Drug effect on 
signalling proteins was studied using phospho-antibody arrays and Western-blotting analysis. 
Interaction between drugs and ABC transporters were characterized using substrate and 
inhibition assays. Finally, in vivo tumor growth and pharmacodynamic response after drug 
treatments were evaluated in xenografts models. 
Results: Evaluation of the phospho-kinase profile in cell-of-origin sarcoma models and/or 
sarcoma primary cell lines evidenced that PI3K/AKT/mTOR, JAK/STAT or SRC were among the 
most highly activated pathways. In striking contrast with the structurally related drug midostaurin, 
EC-70124 efficiently prevented the phosphorylation of these targets and robustly inhibited 
proliferation through a mechanism associated to the induction of DNA damage, cell cycle arrest 
and apoptosis. In addition, EC-70124 was able to partially reduce tumor growth in vivo. 
Importantly, this compound inhibited the expression and activity of ABC efflux pumps involved in 
drug resistance. In line with this ability, we found that the combined treatment of EC-70124 with 
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doxorubicin resulted in a synergistic cytotoxic effect in vitro and increased anti-tumor activity of 
doxorubicin in vivo.  
Conclusion: Altogether, these results uncover the capability of the novel multikinase inhibitor 
EC-70124 to counteract drug resistance in sarcoma and highlight its therapeutic potential when 










Sarcomas comprise a group of aggressive malignancies which are suggested to develop from 
transformed mesenchymal stromal/stem cells (MSCs) [1, 2]. Despite advances in the clinical 
management of these diseases the overall survival for patients presenting with metastatic and 
recurrent disease continues to be dismal [3] and cytotoxic drugs like doxorubicin remain as the 
mainstay for first-line treatments [4, 5]. However, advanced sarcomas often show resistance to 
doxorubicin, mainly through the overexpression of members of ATP binding cassette (ABC) 
transmembrane family of transporters which act as efflux pumps for anti-cancer drugs [6]. 
Therefore, the development of therapeutic strategies able to prevent drug resistance would 
undoubtedly improve current sarcoma treatments [7, 8].  
The phosphotidylinositol-3’ kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling 
pathway is abnormally activated in many sarcomas and alterations in several components of this 
axis have been correlated with poor clinical outcome [9-12]. Specifically, myxoid and round cell 
liposarcomas (MRCLS), an adipocytic tumor characterized by the expression of the fusion oncogene 
FUS-CHOP, frequently show oncogenic events, such as mutations in PI3KCA or overactivation of insulin-
like growth factor I receptor (IGF1R) or SRC signaling, which provoke an abnormal activation of these 
route. [13-18].  
mTOR is a serine/threonine protein kinase that exists in two different complexes (mTORC1 and 
mTORC2). Activated mTORC1 phosphorylates its downstream targets S6 kinase-1, which in turn 
phosphorylates/activates the ribosomal protein S6 (S6), and the eukaryotic initiation factor 4E-
binding protein-1 (4EBP1) resulting in the activation of the synthesis of a panoply of proteins 
involved in cell growth, metabolism and survival [11, 19]. On the other hand, the activation of 
mTORC2 is involved in actin remodeling and may also contribute to complete activation of 
mTORC1 through the activation of AKT earlier in the pathway [9, 19]. Upstream, the 
PI3K/AKT/mTOR pathway may be triggered by the activation several receptor tyrosine kinases 
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(RTKs), such as IGF1R, platelet-derived growth factor receptor (PDGFR) or fibroblast growth 
factor receptor (FGFR), and non-receptor tyrosine kinases, like SRC, whose deregulation 
reportedly plays a role in the tumorigenic process in several types of sarcoma [15, 17, 18, 20].  
Consistent with these findings, the efficiency of several mTOR inhibitors have been evaluated in 
sarcomas [9]. Clinical testing of rapamycin and its derived analogs has provided at best only 
modest results [21]. This limited response may be explained by the fact that these compounds 
are efficient inhibitors of mTORC1 but not mTORC2 which contribute to induce an adaptive 
resistance due to the reactivation of AKT [22]. Therefore, a new generation of inhibitors able to 
target both complexes and/or combinatorial strategies aimed to prevent resistance to mTOR 
inhibitors are being tested in sarcomas [22-24]. 
Targeting several key oncogenic signals with a single agent may constitute an ideal alternative to 
increase efficiency and prevent the activation of resistance mechanisms. In line with this aim, EC-
70124 is a hybrid indolocarbazole analog [25] with a potent multikinase inhibitor spectrum 
affecting key signaling kinases implicated in pro-survival and proliferative pathways. Thus, EC-
70124 have shown antitumor activity in breast, glioblastoma, colorectal and prostate tumors as 
well as in acute myeloid leukemia (AML) associated to the inhibition of a wide variety of targets 
including components of the PI3K/AKT/mTOR, JAK/STAT, NFκB or FLT3 pathways [26-30]. 
Interestingly, midostaurin (PKC-412), an indolocarbazole clinically approved for AML treatment, 
has shown anti-tumor activity in certain sarcoma subtypes [31-33].  
Here, we evaluated the anti-tumor effect properties of EC-70124 and midostaurin in relevant 
sarcoma models and patient-derived primary cell lines. Opposite to midostaurin, EC-70124 
showed strong anti-proliferative effects through a mechanism mediated by mTOR inhibiton. In 
addition, this drug inhibited the expression and activity of ABC transporters and synergized in 




Cell culture, drugs and ethics statement. 
Transformed bone marrow-derived mesechymal stem/stromal cell (hBMSC) lines with or without 
expression of FUS-CHOP were previously generated and characterized (Table S1 and 
Supplemental Information; [34, 35]). Patient-derived primary cell cultures were generated as 
described in Supplemental Information. An overview of patient and tumor characteristics is given 
in table S2. The identity of all cell lines has been authenticated by Short Tandem Repeats 
analysis during the last 3 months. All the cell lines were tested for Mycoplasma monthly using the 
LONZA MycoAlert Mycoplasma Detection Kit (LONZA, Rockland CE) and cultured as previously 
described [34]. EC-70124 was synthesized by a proprietary process by EntreChem S.L. (Oviedo, 
Spain). PKC-412 (midostaurin) was synthesized from staurosporine (Biomar Microbial 
Technologies, León, Spain) and the identity of the isolated product verified by comparison to an 
authentic sample (HPLC, NMR). Stocks of EC-70124, midostaurin, doxorubicin (Sigma, St Louis, 
MO) and torin (Selleckchem, Houston, TX) were prepared as 1 mM solutions in sterile DMSO for 
in vitro experiments, maintained at -20 °C, and brought to the final concentration just before use. 
For in vivo experiments, doxorubicin was prepared in sterile saline solution and administrated 
intra-venenously and EC-70124 was dosed by oral gavage. Human samples and data from 
donors included in this study were provided by the Principado de Asturias BioBank 
(PT17/0015/0023) integrated in the Spanish National Biobanks Network. All experimental 
protocols have been performed in accordance with institutional review board guidelines and were 
approved by the Institutional Ethics Committee of the Hospital Universitario Central de Asturias.  
Tumorsphere culture 
Tumorsphere formation protocol and the analysis of the effects of drugs on tumorsphere cultures 
were previously described [36].  
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Cell viability assays 
The viability of all cell lines in the presence and absence of drugs was determined using the Cell 
Proliferation reagent WST-1 (Roche, Mannheim, Germany) as described before [37]. The 
concentration of half-maximal inhibition of viability (IC50) for each treatment was determined by 
non-linear regression using the graphPad Prism software (La Jolla, CA). The existence of 
synergy in drug combinations was determined by calculating the combination index (CI) as 
described in Supplemental information.  
Western blotting and phospho-kinase antibody arrays 
Whole cell protein extraction and Western blotting analysis were performed as previously 
described [37]. Antibodies used are described in Supplemental Information.  
The phosphorylation status of a wide range of RTKs and downstream signaling nodes was 
evaluated in EC-70124 or midostaurin-treated cells using the PathScan RTK Signaling Antibody 
Array Kit (# 7982, Cell Signaling Technology, Danvers, MA). Protein extraction after treatments, 
array incubation and signal development was performed using the reagents provided by the kit 
according to the manufacturer’s instructions.  
Infrared fluorescent signals in Western blotting and antibody array analysis were detected and 
quantified using a Odyssey Fc imaging system and the software Image Studio from LICOR 
(Lincoln, NE). The signal intensity of the background was subtracted from the signal of each spot, 
and the average of duplicate spots was determined. Next, normalized signal intensity was 
calculated by dividing the mean value in each spot over the mean value in the positive control. 
Cell-cycle analysis  




In γH2AX immunofluorescence experiments, fixation, staining and mounting of the samples were 
performed as previously reported [4]. Antibodies and experimental conditions are described in 
Supplemental Information.  
RT-qPCR assays  
The expression of ABCB1 and ABCG2 was assessed by qPCR as described in Supplemental 
Information.  
Transporter substrate and inhibition assays 
The assessment of the ability of EC-70124 to inhibit ACBB1/MDR1 and ABCG2/BCRP1 or to be 
a substrate for these transporters were performed by Absorption Systems (Exton, PA) as 
described in Supplemental Information.   
In vivo tumor growth 
All experimental protocols were carried out in accordance with the institutional guidelines of the 
University of Oviedo and were approved by the Animal Research Ethical Committee of the 
University of Oviedo prior to the study. Female NOD/SCID mice of 6 weeks old (Janvier Labs, St 
Berthevin, France) were inoculated subcutaneously (s.c.) with 2x106 T5H-FC#1 cells. Once 
tumors reached 200-300 mm3, the mice were randomly assigned to receive vehicle, EC-70124 
(80 mg/Kg, q2dx11, orally), doxorubicin (4 mg/Kg, q4dx3, intra-venous) or the combination of EC-
70124 (40 mg/Kg, q2dx8, orally) and doxorubicin (4 mg/Kg, q4dx3, intravenous), intra-venous. 
Animals were sacrificed by CO2 asphyxiation when tumors of the control series reached 
approximately 1000 mm3 or if severe weight loss were observed. Mean tumor volume differences 
between groups were determined using a caliper (Supplemental Information). The student t test 
was performed to determine the statistical significance between different groups. The F-test was 
used to compare tumor volume growth kinetics. Drug efficacy was expressed as the percentage 
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tumor growth inhibition (%TGI) (Supplemental Information). For pharmacodynamic studies, a 
single dose of each treatment was inoculated into immunodeficient mice carrying tumors of 
approximately 400-500 mm3. Tumors (n=2/3 per group) were collected after 4, 24 or 48 hours, 
minced, washed with PBS and homogenized in ice-cold lysis buffer (1mL/100 mg of tumor; see 
Supplemental Information for buffer composition) using a GentleMACS Dissociator system 
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer instructions. This 
homogenate was centrifuged at 10,000 xg for 20 minutes at 4ºC, and the supernatants containing 
protein extracts were transferred to new tubes and used in Western blotting experiments or to 
analyze the concentration of EC-70124 and doxorubicin by liquid chromatography–mass 
spectrometry.  
Histological analysis.  
Tumor samples were fixed in formol, embedded in paraffin, cut into 4-μm sections, and stained 
with hematoxylin and eosin (H&E). Tumor sections were also subjected to immunohistochemistry 
as previously reported [38] using the antibodies and quantification methods described in 
Supplemental Information. Tumor grade was analyzed in H&E stained preparations using the 







Differential effects of the indolocarbazole analogs EC-70124 and midostaurin in sarcoma. 
To study the anti-tumor effects of indolocarbazole analogs in sarcoma we used previously 
developed cell-of-origin models of undifferentiated pleomorphic sarcoma (MSC-4H-GFP, MSC-
5H-GFP and T-5H-GFP#1) and FUS-CHOP (FC)-expressing MRCLS (MSC-4H-FC, MSC-5H-FC, 
T-4H-FC#3 and T-5H-FC#1) in which hBMSCs were sequentially mutated with up to six 
oncogenic events (see Table S1 and Supplemental information). The evaluation of cell toxicity in 
dose-response experiments showed that, opposite to wild type hBMSCs, all sarcoma models 
were sensitive to nanomolar concentrations of EC-70124 (IC50 values between 180 and 540 nM) 
(Figure 1a-b). To further characterize the cytotoxic effect of EC-70124 we performed similar dose-
response experiments in a panel of primary sarcoma cell lines (described in Table S2 and 
Supplemental information). A subgroup of 5 primary cell lines (CDS1+, CDS17+, SARC6+, 
SARC10+ and GIST-1) show a sensitivity to EC-70124 similar to that observed for the sarcoma 
models (IC50 values between 201 and 343 nM), while another 3 cell lines (SARC1+, SARC3+ and 
SARC4+) were more resistant (IC50 values between 705 nM and 1.3 μM) (Figure 1c). In 
accordance with this cytotoxic effect, EC-70124 treatment induced a dose-dependent apoptotic 
cleavage of PARP both in sarcoma models (MSC-5H-FC and T-5H-FC#1 cells) (Figure 1d) and 
primary cell lines (Figure 1e). In striking contrast to the effect of EC-70124, sarcoma models 
MSC-5H-FC and T-5H-FC#1 were resistant to the treatment with midostaurin (Figure S1a-b) and 
this drug induced only a marginal apoptotic effect compared to that of EC-70124 (Figure 1d). As a 
control, midostaurin was efficient inhibiting proliferation of a leukemia cell line as previously 
shown [29] (Figure S1a). Cell cycle analysis also showed a different response of sarcoma cells to 
the treatment with both indolocarbazole analogs. Cell cycle profiles of MSC-5H-FC and T-5H-
FC#1 cells treated with 1 μM EC-70124 were characterized by a strong arrest in S-phase 
followed by the induction of high levels of apoptosis (Sub-G1 population). On the other hand, cells 
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treated with 1 μM midostaurin quickly arrest in G2/M phase and underwent endoreplication 
without cell division resulting in cell populations with 8n DNA content after 48 hours of treatment 
(Figure 1f). In line with the different ability to induce S-phase arrest, EC-70124, but not 
midostaurin, was able to efficiently induce DNA damage in T-5H-FC cells as indicated by the 
dose-dependent increase of intranuclear γH2AX foci levels (Figure 1g-h and Figure S2).  
Finally, we tested the ability of these indolocarbazole analogs to target cancer stem cell (CSC)-
enriched tumorsphere cultures of MSC-5H-FC and T-5H-FC#1 cells [36]. Again, EC-70124 was 
more efficient than midostaurin in eliminating CSCs (Figure S1c), although its cytotoxic effect on 
CSC subpopulations was lower than that previously observed in non-selected adherent cultures 
(Figure 1a-b) and also much lower than the effect of the mythramicin analog EC-8042, a drug 
with reported activity on sarcoma CSCs [37].  
 
Effect of EC-70124 and midostaurin on the kinase profile of sarcomas 
To gain insights about the mechanistic basis of EC-70124-induced citotoxicity in sarcomas, we 
used phospho-kinase antibody arrays to evaluate the ability of the indolocarbazole analogs to 
inhibit the phosphorylation/activation of 39 relevant receptor tyrosine kinases and signaling 
transducers. In T-5H-FC#1 cells, EC-70124 induced an efficient and durable inhibition of several 
components of the PI3K/AKT/mTOR and MAPK pathways, including phospho-AKT (T308 and 
S473), phospho-S6 (S235/236) and phospho-ERK1/2 (T202/Y204) (Figure 2a-b, Figure S3a and 
Figure S4). On the other hand, midostaurin produced a much reduced and reversible inhibition of 
these targets (Figure 2a-b). Western blotting analyses of time-course (Figure 2c) and dose-
response experiments (Figure 2d) confirmed that EC-70124 is much more efficient than 
midostaurin in inhibiting the phosphorylation of AKT and the mTOR downstream targets S6 and 
4EBP1 in MRCLS models, without affecting total protein levels. As expected, the well-known 
mTOR inhibitor torin was also able to efficiently inhibit all these targets (Figure S3b). 
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Complementary, we calculated the inhibitor binding constants (Kd values) for a panel of kinases 
in the presence of several concentrations of EC-70124 or midostaurin (KdELECT assay, 
DiscoverX). Similar to that observed measuring phosphorylation levels, EC-70124 showed a 
higher potency that midostaurin to bind/inhibit mTOR signaling (S6K1, RSK2, RSK3 and RSK4) 
and cell cycle-related kinases (CHK1, AURKA, AURKB and AURKC) (Table S3).   
As in T5H-FC#1 cells, AKT, S6 and ERK1/2 were the kinases/signaling molecules showing a 
higher level of activation/phosphorylation in three sarcoma primary cell lines. Again, EC-70124 
was able to inhibit the phosphorylation of these targets, with the only exception of ERK1/2 in the 
line CDS1+ and AKT (S473) in the line SARC6+ (Figure 2e-f, Figure S3c and Figure S4). Of note, 
the inhibition of phospho-S6 was complete in all the assayed cell lines. In addition, some of the 
primary cell lines also displayed high levels of phospho-STAT1 (CDS17+ and SARC6+), 
phospho-STAT3 (CDS1+, CDS17+ and SARC6+) and phospho-SRC (CDS1+ and SARC6+) and 
EC-70124 efficiently inhibited these phosphorylations (Figure 2e-f). In Western blotting analysis of 
dose-response experiments we confirmed the ability of EC-70124 to inhibit the phosphorylation of 
phospho-AKT, phospho-S6 and phospho-STAT3 in seven primary cell lines (Figure 2g).  
Overall these results indicate that EC-70124 is a more efficient multi-kinase inhibitor and show a 
more robust anti-proliferative effect than midostaurin in sarcomas. Also, they suggest that mTOR 
signaling inhibition may play a prominent role in EC-70124-induced citotoxicity.   
 
mTOR signaling inhibition mediates EC-70124-induced citotoxicity. 
To study the relevance of the contribution of mTOR signaling inhibition to the anti-tumor effects of 
EC-70124, we analyzed the effects of torin in T-5H-FC#1 cells. We first found that, compared to 
EC-70124 and midostaurin, torin showed an intermediate capacity to reduce cell viability (Figure 
S5a) and did not induce DNA damage (Figure S2). Given that torin is a potent mTOR inhibitor 
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(Figure S3b), we hypothesized that if the inhibition of mTOR signaling is involved in the mediation 
of the cytotoxic effect of EC-70124 we do not expect a great synergy from the combination of this 
indolocarbazole with torin. Conversely, given that midostaurin is a poor inhibitor of mTOR 
signaling, if the inhibiton of mTOR signaling is a relevant mechanism we would expect a higher 
synergistic effect when we combine torin with midostaurin. Investigating this hypothesis we found 
that combination of EC-70124 or midostaurin with increasing concentrations of torin enhanced 
cytotoxicity (Figure S5b-c). However, by representing the data of these combinations normalized 
to the effect of torin alone, we did not find a relevant shift of toxicity curves in the combinations 
with EC-70124 (Figure S5d). Otherwise, we did find an important shift toward higher toxicity in the 
combinations of torin with midostaurin (Figure S5e), thus suggesting a more than additive 
contribution of the mTOR inhibitor to the toxicity of midostaurin. To test whether these 
combinations has synergistic cytotoxic effect we calculated their combination index (CI) using the 
CompuSyn software. In the case of combinations with EC-70124 we found an intermediate level 
of synergism (CI value for ED75=0.44) when we assay combinations of drugs that target between 
40 and 75% of the cells (0.4<Fa<0.7). However, this synergistic effect is lost at combinations of 
higher concentrations of drugs that affect a higher percentage of the cells (Fa>0.8) (Figure S5f). 
This effect may be explained by the fact that at high concentrations of EC-70124 mTOR signaling 
is completely inhibited and a mTOR signaling inhibitor like torin cannot add a further effect. On 
the other hand, and in line with our rationale, the combination of increasing concentrations of torin 
with midostaurin resulted in a constant increase of the CI, which reached the level of strong 
synergism when the fraction of cells affected is higher that 70% (CI value for ED75=0.14) (Figure 
S5f).  
Altogether, the combination of indolocarbazole analogs with inhibitors of mTOR signaling 
suggested that the anti-proliferative action of EC-70124 is, at least in part, mediated by the 




In vivo anti-tumor activity of EC-70124. 
Oral treatment of NOD/SCID mice carrying T-5H-FC#1 xenografts with EC-70124 resulted in a 
moderate tumor growth inhibition. Compared to vehicle treated group, mice treated with 80 mg/Kg 
of EC-70124 every two days showed a percentage of TGI of 26.5% (Figure 3a). Likewise, at the 
end of the experiment, tumor weights of EC-70124-treated mice were significantly lower than 
those of the control group (Figure 3b). Notably, EC-70124 treatment did not cause loss of weight 
(Figure 3c) or other adverse effects. Histological examination of tumors showed that EC-70124-
treated tumors exhibited lower mitotic counts and a significant reduction in tumor grade in 
comparison to untreated tumor samples (Figure 3d-e).  
The pharmacodynamic profile of EC-70124 was obtained by analyzing protein levels in tumors 
collected at different time-points in a sub-cohort of mice (n=2-3) upon a single 80 mg/kg dose 
(Figure 3f). Pharmacodynamic effect of EC-70124 was in agreement with the results obtained in 
cultured cells. Thus, a partial inhibition of the phosphorylation of S6 and AKT was detected in 
tumor tissues 4 hours after the treatment, thus suggesting that same pathways identified in vitro 
are mediating the effects in vivo (Figure 3f). Recovery profile of the proteins analyzed showed 
that the inhibition of the phosphorylation of the mTOR target S6 was sustained for at least 24-48 
hours after dosing, while phospho-AKT showed a faster recovery (Figure 3f).  
 
EC-70124 inhibits the expression and activity of ABC transporters and is not a substrate 
for them. 
Several ABC transporters, such as ABCG2/BCRP1 and ABCB1/MDR1, play major roles in drug 
resistance in tumor cells [6-8]. It has been previously reported that a panel of indolocarbazole 
protein kinase inhibitors, including midostaurin, were able to inhibit the transport activity of 
ABCG2 [39, 40]. Therefore we studied the interaction of EC-70124 with the two members of the 
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ABC family most commonly involved in drug resistance of cancer cells. In functional assays we 
found that EC-70124 efficiently inhibited the pumping activity of both ABCG2 and ABCB1 (Figure 
4a, Table S4 and Table S5) and moreover, these pumps failed to transport this indolocarbazole 
analog (Figure 4b and Table S6). Importantly, EC-70124 was also able to decrease the mRNA 
(Figure 4c) and protein (Figure 4d) expression of ABCG2 and ABCB1 in several MSC-5H and T-
5H cell lines.  
This inhibitory effect of EC-70124 on the expression and activity of ABC transporters suggest 
that, besides its anti-tumor activity, this drug may also play a role in counteracting drug 
resistance. 
 
EC-70124 and doxorubicin shows synergistic cytotoxic effect in vitro and in vivo.  
Doxorubicin-based therapies are still widely used as first-line treatments of both soft tissue and 
bone sarcomas [5]. However, doxorubicin, like many other chemotherapeutic agents, is a well-
known substrate of ABC transporters [41]. Therefore, given the ability of EC-70124 to inhibit ABC 
transporters, we tested whether its combination with doxorubicin may produce a synergistic anti-
tumor effect. First, we found that all sarcoma models were also sensitive to nanomolar 
concentrations of doxorubicin (IC50 values between 74 and 318 nM) (Figure S6). Doxorubicin 
treatment resulted in an up-regulation of phospho-S6, phospho-4EBP and ABCB1, while EC-
70124, alone or in combination with doxorubicin efficiently decreased the levels of these targets 
(Figure 5a). Importantly, the combination of EC-70124 with 100 nM doxorubicin significantly 
shifted toxicity curves and markedly decreased the IC50 of EC-70124 in several sarcoma model 
cell lines but not in wild-type hMSCs (Figure 5b). By calculating the CI of several constant ration 
combinations of EC-70124 and doxorubicin, we confirmed the existence of synergism between 
both drugs in MSC-5H-FC (CI value for ED75=0.30) and T-5H-FC#1 cells (CI value for ED75=0.62) 
(Figure 5c).  
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In vivo activity of the combination was evaluated in T-5H-FC#1 xenografts treated with oral doses 
of 40mg/kg EC-70124 every two days and/or intra-venous doses of 4 mg/kg doxorubicin every 
four days. By measuring the evolution of tumor volumes during the treatment (Figure 6a) and 
tumor weights at the end of the experiments (Figure 6b), we found that, as previously showed, 
EC-70124 caused certain level of tumor growth inhibition (% TGI= 27.2), whereas doxorubicin 
was more efficient in inhibiting tumor growth (% TGI = 68.7). Importantly, the combination of EC-
70124 and doxorubicin was able to reduce tumor volumes (% TGI= 93.7) in a nearly statistically 
significant fashion (P=0.09) and tumor weights in a significant manner (P=0.01) compared to the 
effect of both drugs alone (Figure 6a-b). Of note, mice treated with regimens including 
doxorubicin experienced important weight loss and the experiment had to be suspended on day 
14 (Figure 6c). 
Pharmacodynamic analysis showed that EC-70124 was able to inhibit the phosphorylation of S6 
and AKT even in the presence of doxorubicin, which increased the phosphorylation of S6 in 
individual treatments (Figure 6d). In addition, a notably increase in apoptosis (PARP cleavage) 
was detected in tumors treated with the combination (Figure 6d). Histological examination 
confirmed the inhibition of phospho-S6, in tumors treated with EC-70124 alone or in combination 
with doxorubicin (Figure 6e-f). In addition, tumors treated with doxorubicin alone or in combination 
with EC-70124 exhibited significantly reduced mitotic counts and tumor grade (Figure 6e-f). 
Altogether, these results indicate that the combination of EC-70124 and doxorubicin has a 






Indolocarbazole alkaloids have attracted great attention because of their original structural 
features and their ability to inhibit a wide spectrum of receptor and intracellular signaling kinases 
[25, 42]. Among these compounds midostaurin have been recently approved for the treatment of AML 
patients harboring mutations in FLT3 [43]. In sarcoma, this drug has been found to inhibit the 
transcriptional activity of fusion oncogenes characteristic of alveolar rhabdomyosarcoma (PAX3/FKHR) 
and Ewing sarcoma (EWS/FLI1) as well as exhibited anti-tumor potential in these and other types of 
sarcoma [31-33]. In addition, midostaurin has been show to synergize with anti-tumor agents like HDAC 
inhibitors, oncostatin M, or IGF1R inhibitors in different types of sarcoma [44, 45].  
Here we found that the indolocarbazole analog EC-70124 is much more efficient that midostaurin in 
inhibiting the phosphorylation of ERK1/2 at Thr202 and Tyr204, AKT at Ser473 and Thr308, pS6 at 
Ser235 and Ser236 and 4EBP at Ser65, which are the kinases/kinase substrates more activated among a 
panel of relevant signaling molecules in a cell-of-origin model of MRCLS. In a similar way, EC-70124 has 
recently demonstrated a higher capacity than midostaurin to inhibit several clinically relevant kinases in 
pre-clinical models of AML [29]. In addition, EC-70124 was also able to inhibit the activation of SRC, 
STAT1 and STAT3 which were found activated in several primary sarcoma cell lines. This higher potential 
of EC-70124 as multi-kinase inhibitor in sarcomas correlated with a more potent anti-proliferative effect in 
comparison with midostaurin and the basis of this enhanced toxicity relies on the induction of much higher 
levels of DNA damage followed by a more stringent S-phase arrest and apoptosis. It has been reported 
that midostaurin and other indolocarbazoles inhibit Aurora kinase, resulting in abrogation of the mitotic 
spindle checkpoint and the accumulation of cells with 4N and 8N DNA content [46, 47]. Here we observed 
a similar effect after the treatment of sarcoma cells with midostaurin, although this endoreplication effect is 
not sufficient to efficiently reduce cell viability. In vitro kinase binding affinity assays showed that EC-70124 
inhibited Aurora kinases even more potently than midostaurin (Table S3) and opposite to this drug, EC-
70124 was also a powerfull inhibitor of CHK1, which is a key player in the sensing and the response to 
DNA damage in the S and G2 phases of cell cycle [48]. This differential ability of both drugs to inhibit 
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CHK1 may be responsible for the pronounced S-phase arrest and the increased DNA damage and 
apoptosis observed after the treatment with EC-70124 but not with midostaurin. 
Downstream mTORC1 effectors S6 and 4EBP were the targets whose phosphorylation levels were more 
consistently inhibited by EC-70124 in all the sarcomas cell lines tested. The efficient inhibition of the 
phosphorilation of S6 correlates with the high affinity (low Kd) of EC-70124 for S6K1 (Table S3). This data 
are in line with previously reported activity of EC-70124 in breast and colon cancer [27, 30]. By combining 
EC-70124 or midostaurin with the mTOR inhibitor torin, we studied the role of mTOR signaling in the 
cytotoxic effect of indolocarbazole analogs. Torin induced certain level of toxicity and did not synergize 
with EC-70124, which was an efficient mTOR inhibitor by itself and therefore did not allow for a 
mechanistic synergy with torin. On the other hand, torin synergized with midostaurin, which was a poor 
and transient inhibitor of mTOR signaling. Altogether, these results suggest that, although the inhibition of 
other targets could contribute, the blocking of mTOR signaling plays a key role in EC-70124-induced anti-
proliferative effects. 
Despite the relevant role that PI3K/AKT/mTOR pathway plays in the pathogenesis of several types of 
sarcomas, including MRCLS [14-16], and the promising anti-tumor activity observed in vitro, EC-70124 
showed only a small, although significant, effect in vivo. This effect was accompanied with a partial and 
durable inhibition of phospho-S6 and a transient inhibition of phospho-AKT (S473) which recovered pre-
treatment levels after 24 hours. Several mechanisms of resistance involving the recovering of PI3K/AKT 
signaling after the activation of mTORC2 via IGFR1 or PDGFR signaling have been described for different 
mTOR inhibitors [20, 22, 23]. Therefore, the restoring of AKT signaling may be in the basis of the 
resistance to the treatment with EC-70124. Nevertheless, we have not detected an increased 
phosphorilation of IGF1R or PDGFR after EC-70124-treatment in vitro (Figure S4), thus suggesting that 
other unknown mechanisms may be mediating the reactivation of AKT.  
Signaling mediated by PI3K-AKT-mTOR has been involved in drug resistance in a wide range of tumors 
[9, 19]. Accordingly, mTOR inhibitors were able to restore sensitivity against tyrosin kinase inhibitors and 
chemotherapeutic drugs like doxorubicin, cisplatin or paclitaxel in several types of tumors including 
sarcomas [9, 19, 49]. Apart from the anti-apoptotic and pro-survival signals mediated by PI3K-AKT-mTOR 
signaling, the upregulation of members of ABC family of transporters through the activation of this pathway 
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seems to be another important mechanism of drug resistance [19, 50]. In these regard, several 
Indolocarbazoles have demonstrated its ability to inhibit ABCB1 and/or ABCG2 and reverse drug 
resistance [39, 40]. In addition, several tyrosine kinase inhibitors have been recently reported to increase 
the efficacy of conventional chemotherapeutic agents through mechanisms involving the inhibition and/or 
the expression of different ABC pumps [8]. Here we found that EC-70124 was able to inhibit the enzymatic 
activity and the expression of ABCB1 and ABCG2 and moreover, it was not transported by these pumps. 
In line with this result, we showed that the combination of EC-70124 with doxorubicin produced a 
synergistic decrease of cell viability and a reduction in tumor growth in vivo. These findings suggest that 
the ability of EC-70124 to inhibit ABC transporters maybe in the basis of these enhanced anti-tumor 
potential of the combination. 
Altogether, these results uncover the capability of the novel multikinase inhibitor EC-70124 to 




Aberrant activation of kinases, such as those controlling the PI3K/AKT/mTOR pathway, is a 
recurrent tumor-driving mechanism in sarcomas. Therapies aimed to target these signals 
frequently result in the activation of compensatory routes that cause adaptive resistance. 
Therefore combinatory strategies aimed to inhibit several kinase-mediated pathways at once are 
being widely tested. Here we evaluated the activity of the indolocarbazole analog EC-70124, 
which acts as a wide spectrum multi-kinase inhibitor in sarcomas. This compound demonstrated 
a much potent kinase inhibition activity and anti-proliferative effects than the related drug 
midostaurin in cell-of-origin sarcoma models and primary cell lines. Although, EC-70124 did not 
show a robust in vivo anti-tumor activity by itself, it was able to inhibit several ABC pumps 
resulting in increased anti-tumor activity of doxorubicin in vitro and in vivo. Hence, this study 






MSC: mesenchymal stromal/stem cells 
BMSC: bone marrow-derived mesechymal stem/stromal cell 
ABC: ATP binding cassette 
PI3K: phosphotidylinositol-3’ kinase 
mTOR: mammalian target of rapamycin 
MRCLS: myxoid/round cell liposarcoma 
FUS: fused in sarcoma 
CHOP: C/EBP homologous protein 
S6: ribosomal protein S6  
4EBP1: eukaryotic initiation factor 4E-binding protein-1 
RTK: receptor tyrosine kinase 
IGF1R: insulin-like growth factor I receptor 
PDGFR: platelet-derived growth factor receptor 
FGFR: fibroblast growth factor receptor 
AML: acute myeloid leukemia 
H&E: hematoxylin and eosin 
FFPE: Formalin-fixed paraffin-embedded 
FNCLCC: French Federation of Comprehensive Cancer Centers 
CI: combination index 
CSC: cancer stem cell 
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LEGENDS TO FIGURES 
 
Figure 1. Antiproliferative effects of EC-70124 and midostaurin in sarcoma. (a-c) Cell 
viability (WST1 assay) measured after the treatment of wild-type hMSCs and the indicated MSC-
4H, T-4H (a), MSC-5H and T-5H cells lines (b) or several patient-derived sarcoma primary lines 
(c) with increasing concentrations of EC-70124 for 48 hours. IC50 values for each cell type are 
shown. Error bars represent the standard deviation of at least three independent experiments. (d-
e) Apoptotic cleavage of PARP in MSC-5H-FC and T-5H-FC#1 cells (d) or several primary cell 
lines (e) treated with the indicated concentrations of EC-70124 or midostaurin for 24 hours. The 
expression of β-actin was used as loading control in Western blotting analysis. (f) Time-course 
evolution of the cell cycle distribution of MSC-5H-GFP and MSC-5H-FC cells treated with 1μM 
EC-70124 or midostaurin. Peaks of cell populations with 2n, 4n and 8n DNA content, as well as 
the SubG1 population, are indicated. (g-h) Analysis of γH2AX foci formation after the treatment of 
T-5H-FC#1 cells for 6 hours with the indicated concentrations of EC-70124 or midostaurin. (g) 
Quantification of γH2AX foci was performed by counting more than 200 cells in each condition. 
The percentage of cells presenting high (>10 foci) or low level (<10 foci) of DNA damage is 
displayed. Error bars represent the standard deviation. (h) Representative merged images 
(γH2AX immunodetection and DAPI staining) of immunostaining experiments showing a dose-
dependent increase in γH2AX foci formation following EC-70124 treatment. Scale bars= 50 μm. A 
version of this panel showing separate γH2AX-asocciated and DAPI fluorescence is displayed as 
Figure S2. 
 
Figure 2. Kinase inhibitory profile of EC-70124 and midostaurin. (a & e) Phospho-kinase 
antibody arrays showing the phosphorylation/activation status of a panel of kinases in T-5H-FC#1 
cells after the indicated treatments with EC-70124 or midostaurin (a) or in four primary sarcoma 
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cell lines treated or not with 1 μM EC-70124 for 24 hours (e). (b & f) Quantification of the levels of 
the indicated phospho-proteins in the kinase arrays loaded with T-5H-FC#1 (b) or sarcoma 
primary cell lines samples (f). Complete images of the phospho-kinase antibody arrays and the 
quantification of all analyzed kinases in T-5H-FC#1 and primary cell lines are presented as 
Figures S3A&C and S4 respectively. (c, d & g) Western blotting analysis of the indicated 
indicated proteins in T-5H-FC#1 cells treated with 1μM EC-70124 or midostaurin for the indicated 
times (c), in MSC-5H-FC and T-5H-FC#1 cells treated with the indicated concentrations of EC-
70124 for 24 hours (d) and in a panel of primary cell lines treated with 1μM EC-70124 for the 
indicated times (g). Error bars in protein quantifications represent the standard deviation of two 
duplicates. 
 
Figure 3. In vivo anti-tumor activity of EC-70124. NOD/SCID mice with established T-5H-FC#1 
tumor xenografts were randomly assigned to three different groups (n=7 per group) and treated 
by oral gavage with either vehicle or EC-70124 at 80 mg/kg every two days. (a) Curves 
representing the mean tumor volume of T-5H-FC#1 xenografts during the treatments. Drug 
efficacy expressed as the percentage of TGI at day 21 is indicated. (b) Tumor weight at the end 
of the experiment. (c) Body weights of mice during the treatments. (d-e) Pathological analysis of 
formalin-fixed paraffin embedded xenografts extracted from mice treated as in panel A. (d) 
Representative images of the H&E staining of control and EC-70124-treated tumors. Mitotic cells 
(red arrows) are indicated. Scale bars= 50 μm. (e) Quantification of mitosis [number of mitotic 
figures per 10 high power fields (40X)] and tumor grade score according to FNCLCC system in 
tumors from the indicated series. (f) intra-tumor phosphorylation levels (Western blotting analysis) 
of the key targets (g) in samples collected at the indicated time-points from mice treated with a 
single oral dose of 80 mg/kg EC-70124. Error bars represent the SEM and asterisks indicate 
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statistically significant differences between EC-70124-treated and control groups (*:p<0.05; two-
sided Student t test).  
 
Figure 4. Effect of EC-70124 on ABC transporters expression and activity. (a) ABCG2 and 
ABCB1 functional inhibition assay for EC-70124. Cladribine and digoxin were used as known 
substrates and Ko243 and valspodar were used as known inhibitors for ABCG2 and ABCB1 
respectively. A complete summary of experimental results is shown in Tables S3 and S4. (b) 
ABCG2 and ABCB1 functional substrate assay for EC-70124. Ko243 and valspodar were used as 
transporter inhibitors for ABCG2 and ABCB1 respectively. A complete summary of experimental 
results is shown in Table S5. (c) Relative mRNA expression of ABCG2 and ABCB1 genes in 
MSC-5H-GFP and MSC-5H-FC cells treated with the indicated concentrations of EC-70124 for 24 
hours. Error bars represents the standard deviation of three independent experiments and 
asterisks indicate a statistically significant difference with the respective untreated samples 
(*:p<0.05; two-sided Student t test). (d) Western blotting analysis of ABCG2, ABCB1 and β-actin 
after the indicated treatments with EC-70124.  
  
Figure 5. EC-70124 and doxorubicin shows synergistic cytotoxic effect. (a) Western blotting 
analysis of the indicated proteins after the indicated treatments with EC-70124 and/or 
doxorubicin. (b) Cell viability curves representing the IC50 shift observed after 48 hours-treatments 
of the indicated cell lines with EC70124 alone or in combination with 0.1 μM doxorubicin. Error 
bars represents the standard deviation of three independent experiments. (c) Combination index 
plots (mean and standard deviation) for constant ratio combinations of EC-70124 and doxorubicin 
(1:1) in MSC-5H-FC and T-5H-FC cells generated using the CompuSyn software. The CI (± 
standard deviation) values for ED50, ED75 and ED90 combination doses as calculated by the 




Figure 6. In vivo effect of EC-70124 and doxorubicin combination. T-5H-FC#1 established 
xenografts were randomly assigned to four different groups (n=7 per group) and treated with 
vehicle(s), with EC-70124 (orally) at a dose of 40 mg/kg every two days, with doxorubicin (intra-
venous) at a dose of 4 mg/kg on days 0, 4 and 8, or with a combination of both drugs. (a) Curves 
representing the mean tumor volume of T-5H-FC#1 xenografts during the treatments. Drug 
efficacy expressed as the percentage of TGI at day 14 is indicated. (b) Tumor weight at the end 
of the experiment. (c) Body weights of mice during the treatments. (d) Intra-tumor phosphorylation 
levels (Western blotting analysis) of the key targets in samples collected following 0 and 4 hours 
of a single dose of the previously described treatments. (e-f) Pathological analysis of formalin-
fixed paraffin embedded xenografts extracted from mice treated as in panel A. (e) H&E staining 
and immuno-staining detection of phospho-S6. mitotic cells (red arrows) are indicated. Scale 
bars= 50 μm. (f) Quantification of tumor-related features including mitosis [number of mitotic 
figures per 10 high power fields (40X)] and tumor grade score according to FNCLCC system and 
levels of phospho-S6 [number of cell showing positive staining per 10 high power fields (40X)] in 
tumors from the indicated series. Error bars represent the SEM and asterisks indicate statistically 
significant differences between groups. Extra sum-of-squares F Test were used in panel a and 
2wo-sided Student t test were used in panels b,d and g (*:p<0.05; **:p<0.01;).  
 
 
 
 
 
